WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318500
CAS#: 65652-44-0 (acetate)
Description: Pirbuterol Acetate is a short-acting β2 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma as a breath-activated metered-dose inhaler.
Hodoodo Cat#: H318500
Name: Pirbuterol Acetate
CAS#: 65652-44-0 (acetate)
Chemical Formula: C14H24N2O5
Exact Mass: 0.00
Molecular Weight: 300.355
Elemental Analysis: C, 55.98; H, 8.05; N, 9.33; O, 26.63
Related CAS #: 38029-10-6 (HCl) 38677-81-5 (free base) 65652-44-0 (acetate)
Synonym: Pirbuterol Acetate; Maxair; Pirbuterol acetate [USAN]; EINECS 265-862-4; Pirbuterol acetate (USAN); pirbuterol sulfate; pyrbuterol;pirbuterol acetate salt; pirbuterol dihydrochloride; 3M brand of pirbuterol acetate; CP 24315-1; CP-24,314-1; CP-24315-1;
IUPAC/Chemical Name: 6-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)pyridin-3-ol; acetic acid
InChi Key: QSXMZJGGEWYVCN-UHFFFAOYSA-N
InChi Code: InChI=1S/C12H20N2O3.C2H4O2/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8;1-2(3)4/h4-5,11,13,15-17H,6-7H2,1-3H3;1H3,(H,3,4)
SMILES Code: CC(=O)O.CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 300.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Littner MR, Tashkin DP, Calvarese B, Bautista M. Acute bronchial and
cardiovascular effects of increasing doses of pirbuterol acetate aerosol in
asthma. Ann Allergy. 1982 Jan;48(1):14-20. PubMed PMID: 7055342.
2: Levinsky HV, Breckenridge C, Lough R, Gonci DA, McIlhenny HM, Qureshi S. Six
month inhalation studies of pirbuterol acetate aerosol in the beagle dog and
squirrel monkey. Fundam Appl Toxicol. 1981 Nov-Dec;1(6):426-31. PubMed PMID:
7185594.
3: Derksen FJ, Olszewski M, Robinson NE, Berney C, Lloyd JW, Hakala J, Matson C,
Ruth D. Use of a hand-held, metered-dose aerosol delivery device to administer
pirbuterol acetate to horses with 'heaves'. Equine Vet J. 1996 Jul;28(4):306-10.
PubMed PMID: 8818596.
4: Bronsky EA, Debelic M, Pujet JC, Hahn M. Ease-of-use study of pirbuterol
acetate in the Autohaler actuator in three countries: the United States, Germany,
and France. J Asthma. 1993;30(6):439-43. PubMed PMID: 8244913.
5: Chodosh S, Crooks LA, Tuck J. Comparative effects of pirbuterol acetate,
metaproterenol, and placebo aerosols on pulmonary function and incidence of
cardiac ectopy. J Asthma. 1989;26(5):309-15. PubMed PMID: 2484663.
